Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial

JAMA Netw Open. 2023 Apr 3;6(4):e2310877. doi: 10.1001/jamanetworkopen.2023.10877.
No abstract available

Plain language summary

This secondary analysis of a randomized clinical trial investigates the relative effectiveness and safety of the sodium-glucose cotransporter-2 inhibitor dapagliflozin for Black vs White patients with chronic kidney disease (CKD) in North and South America.

Publication types

  • Randomized Controlled Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Glucosides / therapeutic use
  • Humans
  • Hypoglycemic Agents
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / drug therapy
  • White*

Substances

  • dapagliflozin
  • Glucosides
  • Hypoglycemic Agents

Associated data

  • ClinicalTrials.gov/NCT03036150